Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
企業コードRYTM
会社名Rhythm Pharmaceuticals Inc
上場日Oct 05, 2017
設立日2013
最高経営責任者「CEO」- -
従業員数283
証券種類Ordinary Share
決算期末Oct 05
本社所在地222 Berkeley Street
都市BOSTON
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号02116
電話番号18572644280
ウェブサイトhttps://rhythmtx.com/
企業コードRYTM
上場日Oct 05, 2017
設立日2013
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし